These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 35992968)

  • 21. Epidemiological characteristics of 17 imported patients infected with SARS-CoV-2 Omicron variant.
    Liu X; Chen M; Zhou Z; Chen D; Mo J; Liu J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Mar; 47(3):344-351. PubMed ID: 35545327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.
    Xia S; Wang L; Zhu Y; Lu L; Jiang S
    Signal Transduct Target Ther; 2022 Jul; 7(1):241. PubMed ID: 35853878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
    Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
    Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
    Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
    Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
    Xiang T; Wang J; Zheng X
    Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.
    Alkhatib M; Salpini R; Carioti L; Ambrosio FA; D'Anna S; Duca L; Costa G; Bellocchi MC; Piermatteo L; Artese A; Santoro MM; Alcaro S; Svicher V; Ceccherini-Silberstein F
    Microbiol Spectr; 2022 Apr; 10(2):e0273221. PubMed ID: 35352942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodies.
    Schulz SR; Hoffmann M; Roth E; Pracht K; Burnett DL; Mazigi O; Schuh W; Manger B; Mielenz D; Goodnow CC; Christ D; Pöhlmann S; Jäck HM
    Eur J Immunol; 2022 Jun; 52(6):970-977. PubMed ID: 35253229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omicron (B.1.1.529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world? -An overview of current evidence and counteracting strategies.
    Sah R; Rais MA; Mohanty A; Chopra H; Chandran D; Bin Emran T; Dhama K
    Int J Surg Open; 2023 Jun; 55():100625. PubMed ID: 37255735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron.
    Zhu KL; Gao HX; Yao L; Rong J; Yang L; Zhang Z; Jiang P; Duan LJ; Wang GL; Dai EH; Ma MJ
    J Infect Dis; 2022 Nov; 226(9):1551-1555. PubMed ID: 35429398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of vaccines on clinical characteristics of convalescent adult patients infected with SARS-CoV-2 Omicron variant: A retrospective study.
    Wang J; Dong H; Zhao J; Li T; Wang M; Zhou C; Mu H
    Front Microbiol; 2023; 14():1096022. PubMed ID: 37065120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities.
    Alam MS
    Heliyon; 2023 Feb; 9(2):e13285. PubMed ID: 36744070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
    Zhou H; Møhlenberg M; Thakor JC; Tuli HS; Wang P; Assaraf YG; Dhama K; Jiang S
    Clin Microbiol Rev; 2022 Sep; 35(3):e0001422. PubMed ID: 35862736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.
    Dhama K; Nainu F; Frediansyah A; Yatoo MI; Mohapatra RK; Chakraborty S; Zhou H; Islam MR; Mamada SS; Kusuma HI; Rabaan AA; Alhumaid S; Mutair AA; Iqhrammullah M; Al-Tawfiq JA; Mohaini MA; Alsalman AJ; Tuli HS; Chakraborty C; Harapan H
    J Infect Public Health; 2023 Jan; 16(1):4-14. PubMed ID: 36446204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
    Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():946318. PubMed ID: 35928813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.